A widespread failure of local NHS bodies to consistently follow national guidelines on the prescribing of a thyroid drug is causing harm to patients, says a significant new report published today. The report shows that liothyronine, a drug used in the treatment of underactive thyroid (hypothyroidism), is not being routinely provided across the country to the people who need it.
The evidence gathered shows that vulnerable people have ended up with depression, diabetes, heart problems, weight gain, high cholesterol and exhaustion from having this drug either taken away or not prescribed in the first place. The case studies also show people being unable to work and trying to find ways of funding the drug privately.
This is all despite NHS England approved guidance from last year stating that liothyronine should be provided to those who really need it.
The report, which was requested by the Department of Health, has been produced by a consortium of thyroid patient organisations, with guidance from the British Thyroid Association – the UK’s body for thyroid specialists.
Read the full dossier here: http://bit.ly/LiothyronineDossier2018
Kijk voor meer informatie ook eens op Schildkliertje.
Raadpleeg altijd een arts als je twijfelt over je gezondheid.
Het Schildklierforum kan niet worden beschouwd als vervanging van een consult of een behandeling.